Achieve Life Sciences (Achieve Life Sciences) ROIC % : -134.16% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Achieve Life Sciences ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Achieve Life Sciences's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -134.16%.

As of today (2024-04-30), Achieve Life Sciences's WACC % is 15.88%. Achieve Life Sciences's ROIC % is -194.14% (calculated using TTM income statement data). Achieve Life Sciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Achieve Life Sciences ROIC % Historical Data

The historical data trend for Achieve Life Sciences's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achieve Life Sciences ROIC % Chart

Achieve Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROIC %

Get a 7-Day Free Trial

-337.69

-296.42

-674.01

-321.53

-128.53

Achieve Life Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROIC %	Get a 7-Day Free Trial															-352.85	-170.71	-261.71	-654.66	-134.16

Competitive Comparison of Achieve Life Sciences's ROIC %

For the Biotechnology subindustry, Achieve Life Sciences's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Achieve Life Sciences's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's ROIC % distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's ROIC % falls into.

Achieve Life Sciences ROIC % Calculation

Achieve Life Sciences's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

	ROIC % (A: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2022 )	+	Invested Capital (A: Dec. 2023 ))	/ count )
=	-27.25 * ( 1 - 0% )	/	( (20.448	+	21.953)	/ 2 )
=	-27.25	/	21.2005
=	-128.53 %

where

	Invested Capital		(A: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	29.971	-	3.792	-	( 24.721	-	max(0, 21.599	-	27.33	+	24.721	))
=	20.448

	Invested Capital		(A: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	19.371	-	1.249	-	( 15.496	-	max(0, 20.813	-	16.982	+	15.496	))
=	21.953

Achieve Life Sciences's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

	ROIC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-17.544 * ( 1 - 0% )	/	( (4.201	+	21.953)	/ 2 )
=	-17.544	/	13.077
=	-134.16 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	24.337	-	2.321	-	( 19.869	-	max(0, 4.082	-	21.897	+	19.869	))
=	4.201

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	19.371	-	1.249	-	( 15.496	-	max(0, 20.813	-	16.982	+	15.496	))
=	21.953

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

Achieve Life Sciences (NAS:ACHV) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Achieve Life Sciences's WACC % is 15.88%. Achieve Life Sciences's ROIC % is -194.14% (calculated using TTM income statement data).

Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Achieve Life Sciences ROIC % Related Terms

Thank you for viewing the detailed overview of Achieve Life Sciences's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Achieve Life Sciences (Achieve Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (NAS:ACHV) » Definitions » ROIC %

Comparable Companies

Traded in Other Exchanges

SP4P:Germany

Address

22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021

Website

https://www.achievelifesciences.com

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.

Executives

John Bencich	officer: CFO and PFO	2401 FOURTH AVENUE, SUITE 1050, SEATTLE WA 98121
Stuart Duty	director	22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Sellig	director	22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Braxton King	director	91 JAMES AVENUE, ATHERTON CA 94027
Dialectic Life Sciences Spv Llc	10 percent owner	C/O DIALECTIC LS MANAGER LLC, 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Ls Manager Llc	10 percent owner	119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
John Fichthorn	10 percent owner	C/O DIALECTIC CAPITAL MANAGEMENT, LLC, 17 STATE STREET, SUITE 3930, NEW YORK NY 10004
Dialectic Capital Management, Lp	10 percent owner	119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Partners, Llc	10 percent owner	2ND FLOOR 119 ROWAYTON AVE, NORWALK CT 06853
Vaughn B Himes	director	C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Financial Group Svb	10 percent owner	2270 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii, Llc	10 percent owner	2770 SAND HILL ROAD, MENLO CITY CA 94025
Svb Innovation Credit Fund Viii, L.p.	10 percent owner	C/O SVB INNOVATION CREDIT PARTNERS VIII, 2770 SAND HILL ROAD, MENLO PARK CA 94025
Innovation Credit Fund Viii-a, L.p.	10 percent owner	2770 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii-a, Llc	10 percent owner	2770 SAND HILL ROAD, MENLO CITY CA 94025